RECRUITINGOBSERVATIONAL

Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

Evaluation of the Contribution of Glypican-3 as a Pronostic Factor in Patients With Advanced Hepatocellular Carcinoma Treated by Immunotherapy

About This Trial

Recently, the positive results of the Imbrave 150 study (randomized study comparing Atezolizumab+Bevacizumab versus Sorafenib) prompted investigators to redefine their management strategy for advanced HCC by proposing the combination Atezolizumab+ Bevacizumab as first-line treatment in these patients. Identifying new predictive biomarkers of response is essential to optimize the identification of patients who will benefit from immunotherapy. Glypican-3 (GPC-3) is a cell surface glycoprotein that belongs to the family of heparan sulfate chain proteoglycan that is directly implicated in several cancers and more particularly in HCC. GPC-3 overexpression in serum predicts a poor prognosis for patients with HCC and is associated with early tumor recurrence. Through this study, the investigators want to determine whether the concentration of circulating GPC-3 alone, or in combination with other biomarkers used in current practice (PIVKA, AFP) could predict the response to treatment with Atezolizumab/Bevacizumab and OS.

Who May Be Eligible (Plain English)

Who May Qualify: - 18 years ≤ age \< 90 years - Diagnosed with HCC developed on a cirrhotic liver or on chronic liver disease that has not reached the stage of cirrhosis regardless of the etiology diagnosed according to the diagnostic criteria for TNCD updated in June 2021 (1) - Having an indication for systemic therapy with Atezolizumab+Bevacizumab validated in multidisciplinary meeting according to the current recommendations of cancer societies. - Understanding the French language. - Having been informed and accepted to participate to the study. Who Should NOT Join This Trial: - HIV or known immune deficiency or immunosuppressive treatment - autoimmune conditions (where your immune system attacks your own body)s or other immunotherapies - History of portosystemic shunt or liver transplantation - Sepsis, vasoconstrictor drugs. - Pregnant or breastfeeding women - Protected populations: under guardianship or curators Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * 18 years ≤ age \< 90 years * Diagnosed with HCC developed on a cirrhotic liver or on chronic liver disease that has not reached the stage of cirrhosis regardless of the etiology diagnosed according to the diagnostic criteria for TNCD updated in June 2021 (1) * Having an indication for systemic therapy with Atezolizumab+Bevacizumab validated in multidisciplinary meeting according to the current recommendations of cancer societies. * Understanding the French language. * Having been informed and accepted to participate to the study. Exclusion Criteria: * HIV or known immune deficiency or immunosuppressive treatment * Autoimmune diseases or other immunotherapies * History of portosystemic shunt or liver transplantation * Sepsis, vasoconstrictor drugs. * Pregnant or breastfeeding women * Protected populations: under guardianship or curators

Treatments Being Tested

OTHER

Quantitative assay of GlypicanPC-3

Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein

Locations (1)

Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière

Paris, France